Mellozzan (melatonin) is now Reimbursed
The Swedish Dental and Pharmaceutical Benefits Agency (TLV) has today decided that Mellozzan (melatonin) tablets 0.5mg, 1mg, 2mg, 3mg, 4mg, 5mg should be included in the pharmaceutical benefit (reimbursement) system with a limitation to the indication "Insomnia in children and adolescents 6 - 17 years with ADHD where sleep hygiene measures have been insufficient”.
5-7% of children and young people in Sweden have ADHD according to the National Board of Health and Welfare, and the incidence of children with sleep difficulties (insomnia) is very high, up to 80%, among these. The result is a vicious circle where lack of sleep aggravates ADHD symptoms during the day, which in turn negatively affects sleep at night. Not only the child, but also parents and other family members experience a reduced quality of life due to this, studies show”, says Christer Fåhraeus, CEO of EQL Pharma. “Melatonin, which is the active substance in Mellozzan, is also a body-specific hormone and is today classified as the only permitted pharmaceutical for these children. But it is important that they do not take a larger dose than necessary, which is why we offer 6 different strengths. "
For further information, please contact:
Christer Fåhraeus
CEO, EQL Pharma AB (publ)
Phone: +46 (0) 705 – 60 90 00
E-mail: christer.fahraeus@eqlpharma.com
Website: www.eqlpharma.com
EQL Pharma AB (publ) in short
EQL Pharma AB specializes in developing and selling generics, i.e. medicines that are medically equivalent to originator medicines. The company currently has 17 niche generics (i.e. generics with little or no competition apart from the originator drug) approved in the Nordic markets. In addition to these, there exist a significant pipeline of additional niche generics for launch in 2021 and beyond. The business is currently entirely focused on prescription drugs. EQL Pharma AB conducts its operations in Lund, employs 10 people and is listed on the Spotlight Stock Market. EQL Pharma AB conducts extensive development work in collaboration with leading contract manufacturers and major pharmaceutical companies in the EU, India and China, among others.